Abstract
Effect of conventional and sustained release sodium valproate on serum leptin and some liver function tests in epileptic patients
Highlights
body mass index (BMI), serum albumin, ALT, alkaline phosphatase (ALP) and serum direct bilirubin (DB) did not change significantly compared with the controls (Table 1)
Higher than that in patients treated with sustained release sodium valproate
The current study demonstrated significant increase in BMI in epileptic patients receiving conventional sodium valproate, but it was not confirmed with epileptic patients receiving sustained release sodium valproate
Summary
To compare the effect between conventional and sustained released sodium valproate monotherapy on serum leptin, body mass index (BMI) and some liver function tests including serum alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), albumin, total bilirubin (TB) and direct bilirubin (DB) in epileptic patients. Patients and methods: The study is a case control study It included 40 epileptic patients on conventional sodium valproate at doses 400-800 mg per day, and 42 patients on sustained released sodium valproate at doses 500-1000 mg per day. Blood samples were taken from the patients and controls and analyzed for serum ALT, ALP, AST, albumin, total bilirubin and direct bilirubin. Results: Serum leptin, ALT, ALP, AST and TB in epileptic patients treated by conventional sodium valproate were significantly (p < 0.05) higher than that in patients treated with sustained release sodium valproate.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
